What's new? Log in Free sign up

Alpha Tau Medical (DRTS)

Company Profile

Company profile

Ticker

DRTS, DRTSW

Exchange

Website

www.alphatau.com

CEO

Mr. Uzi Sofer

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Ares Capital • Becton, Dickinson and • Stryker • Boston Scientific • Solventum • Baxter International • Teleflex • Hercules Capital • ResMed ...

Former names

Flying Eagle Acquisition Corp.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

DRTS stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Alpha Tau to Participate in March Investor Conferences

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Report of Foreign Private Issuer

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Report of Foreign Private Issuer

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Latest ownership filings

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart DRTS financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

DRTS institutional ownership history Ownership history

4.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	37	28	+32.1%
Opened positions	18	23	-21.7%
Closed positions	9	22	-59.1%
Increased positions	3	4	-25.0%
Reduced positions	2	1	+100.0%

13F shares	Current	Prev Q	Change
Total value	2.42 bn	795.16 mm	+204.9%
Total shares	3.36 mm	3.76 mm	-10.7%
Total puts	0.00	0.00
Total calls	712.99 k	662.50 k	+7.6%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Corbin Capital Partners	960.48 k	$182.54 mm	-24.3%
MMCAP International Inc. SPC	447.62 k	$85.09 mm	0.0%
Levin Capital Strategies	307.33 k	$731.43 mm	NEW
HighTower Advisors	230.70 k	$549.00 mm	NEW
Chicago Partners Investment	215.82 k	$35.07 mm	0.0%
Walleye Capital	201.47 k	$38.30 mm	0.0%
Moore Capital Management	175.00 k	$35.00 mm	0.0%
Mariner	134.64 k	$114.83 mm	+43.4%
Walleye Trading	114.63 k	$21.79 mm	0.0%
Wolverine Asset Management	86.11 k	$16.37 mm	+11.9%

Largest transactions	Shares	Bought/sold	Change
Corbin Capital Partners	960.48 k	-308.04 k	-24.3%
Levin Capital Strategies	307.33 k	+307.33 k	NEW
Atalaya Capital Management	0.00	-280.47 k	EXIT
HighTower Advisors	230.70 k	+230.70 k	NEW
TENOR CAPITAL MANAGEMENT	0.00	-150.00 k	EXIT
Whitebox Advisors	0.00	-146.26 k	EXIT
LMR Partners	0.00	-112.99 k	EXIT
Jane Street	0.00	-105.69 k	EXIT
Circle Wealth Management	0.00	-80.00 k	EXIT
Kim	0.00	-63.64 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Alpha Tau Receives Medical Device Single Audit Program Certification

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the achievement of Medical Device Single

Alpha Tau Announces Upcoming Presentation Of An Abstract Entitled "Interim Analysis Of Feasibility, Safety, And Tumor Control In Two First-In-Human Trials Of A Novel Alpha-Emitting Radionuclide For Pancreatic Adenocarcinoma" At 2025 ASCO GI Symposium And At Company R&D Update Day

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that an abstract entitled "Interim analysis

Press releases

From Benzinga Pro

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.